Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 2 of 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    ALDH18A1 Expression Profiling in Non-small Cell Lung Cancer through Bioinformatics and Experimental Approaches
    (Mongolian National University of Medical Sciences, 2026-05-21)
    Wurihan
    ;
    Yirigui
    ;
    Jie Cheng
    ;
    ;
    Objective: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. The molecular mechanisms of NSCLC are still not fully understood. This study used bioinformatics analysis of public databases to identify potential biomarkers and therapeutic targets. This study used integrated bioinformatics analyses to identify candidate oncogenes associated with in NSCLC. Tissue microarray-based immunohistochemistry was then performed to characterize the protein expression pattern of ALDH18A1 in NSCLC tissues and to preliminarily evaluate its potential as a biomarker. Methods: In this study, TCGA transcriptomic data were analyzed by weighted gene co-expression network analysis (WGCNA), differential expression analysis, least absolute shrinkage and selection operator (LASSO) regression, and random forest analysis to identify ALDH18A1 as a candidate gene in NSCLC. The protein expression of ALDH18A1 was then examined by immunohistochemistry (IHC) using tissue microarrays (TMAs) containing 80 lung squamous cell carcinoma samples, 52 lung adenocarcinoma samples, and their paired adjacent normal tissues. Results: In this study, WGCNA, differential expression analysis, LASSO regression, and random forest analysis identified ALDH18A1 as a key candidate gene in NSCLC. Immunohistochemical analysis showed that the expression level of ALDH18A1 protein was significantly higher in NSCLC tissues than in paired adjacent normal tissues (p < 0.05). Conclusions: ALDH18A1 is markedly upregulated in NSCLC and appears to contribute to tumorigenesis and disease progression, highlighting its promise as a potential diagnostic biomarker and a candidate target for therapeutic intervention.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Association between prostate cancer development and TARBP1
    (Mongolian National University of Medical Sciences, 2025-03-31) ; ; ; ;
    Objective: Prostate cancer is the most frequent cancer among elderly men worldwide and second cause of cancer-related deaths in man. Prostate cancer characterized a clinically heterogeneous and genetic alterations in cells play a pivotal role in carcinogenesis. A detailed understandings of the genetic alterations in cancer cells are important for developing new therapeutic medicine. Transactivation response RNA-binding protein1 (TARBP1) encodes a protein with RNA-binding, tRNA methyltransferase activity, and RNA interference regulation functions, but its association with prostate cancer remains unclear. The aim of this study was to investigate clinical significance of TARBP1 in prostate cancer. Methods: Relative messenger ribonucleic acid (mRNA) and protein expression of TARBP1 in prostate cancer cell and tumor tissue was determined by qRT-PCR and Western blot analysis. LNCaP cells with lentivirus vector to silence the expression of TARBP1 were injected into nude mice. After 24 days, the mice were killed and tumor tissues were excised. The size of tumors was measured using a ruler and body weight of mice were weighed using a scale. Results: Through qRT-PCR and Western blot analysis, we validated that the expression levels of TARBP1 was decreased in TARBP1-knockdown prostate cancer cell compared with cells transfected with negative control LV-shNC RNA. The tumor growths were significant smaller in the group B (LNCaP-LV-shTARBP1) compared with group A (LNCaP-LV-shNC). Knocking down TARBP1 significantly suppressed the tumor progression of BALB/C nude xenograft. Moreover, body weight of mice in LNCaP-LV-shNC group increased significant slowly compared with LNCaP-LV-shTARBP1 group. The result of western blot analysis for TARBP1 in tumor tissues from xenograft nude mice bearing orthotopic LNCaP tumors shows that the expression of TARBP1 was also significantly decreased in the LNCaP-LV-shTARBP1 group compared with LNCaP-LV-shNC group (p < 0.05). Conclusion: We revealed that the TARBP1 highly expressed in prostate cancer and its role in promoting tumor growth. TARBP1 could serve as a potential therapeutic target for prostate cancer treatment and it is also a biomarker for tumor diagnosis and prognosis.